

## Cover Figure

Immunohistochemical analysis of skin tissue biopsies from an individual with acute graft-versus-host-disease. Scattered ICOS+ activated lymphocytes were observed at the dermo-epidermal junction, superficial dermis and around the adnexal follicular epithelium. Figure taken from the article by Maria Cuzzola and colleagues on page 1532.

## Hematology News

- 1453 **Widespread over-expression of the non-clustered homeobox gene *HLX* in acute myeloid leukemia**  
*Stefan Fröhling*

## Editorials and Perspectives

- 1454 **Is it time to abandon RHAMM/HMMR as a candidate antigen for immunotherapy of acute myeloid leukemia?**  
*Dolores J. Schendel*
- 1456 **Survivin: a new player during erythroblast maturation**  
*Wataru Nunomura and Kenichi Sawada*

## Review Articles

- 1459 **Infections in myelodysplastic syndromes**  
*Andréa Toma, Pierre Fenaux, François Dreyfus, and Catherine Cordonnier*

## Original Articles and Brief Reports

### Erythropoiesis & Its Disorders

- 1471 **A novel role for survivin in erythroblast nucleation**  
*Ganesan Keerthivasan, Hui Liu, Jacob M. Gump, Steven F. Dowdy, Amittha Wickrema, and John D. Crispino*
- 1480 **Erythropoietin-driven signaling ameliorates the survival defect of DMT1-mutant erythroid progenitors and erythroblasts**  
*Monika Horvathova, Katarina Kapralova, Zuzana Zidova, Dalibor Dolezal, Dagmar Pospisilova, and Vladimir Divoky*

### Iron Metabolism & Its Disorders

- 1489 **Endoplasmic reticulum anchored heme-oxygenase 1 faces the cytosol**  
*Yehonatan Gottlieb, Marianna Truman, Lyora A. Cohen, Yael Leichtmann-Bardoogo, and Esther G. Meyron-Holtz*

### Red Cell Disorders

- 1494 **Production of the effector cytokine interleukin-17, rather than interferon- $\gamma$ , is more strongly associated with autoimmune hemolytic anemia**  
*Andrew M. Hall, Omar M. Zamzami, Natasha Whibley, Daniel P. Hampsey, Anne M. Haggart, Mark A. Vickers, and Robert N. Barker*

### Blood Coagulation

- 1501 **An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies**  
*Nakisa Khorsand, Nic J.G.M. Veeger, Reinier M. van Hest, Paula F. Ypma, Jeroen Heidt, and Karina Meijer*

### Thrombosis

- 1507 **Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded**  
*Renée A. Douma, Melanie Tan, Roger E.G. Schutgens, Shannon M. Bates, Arnaud Perrier, Cristina Legnani, Douwe H. Biesma, Jeffrey S. Ginsberg, Henri Bounameaux, Gualtiero Palareti, Marc Carrier, Gerben C. Mol, Grégoire Le Gal, Pieter W. Kamphuisen, and Marc Righini*

### Transfusion Medicine and Cell Processing

- 1514 **Arachidonic acid depletion extends survival of cold-stored platelets by interfering with the [glycoprotein Ib $\alpha$  – 14-3-3 $\zeta$ ] association**  
*Dianne E. van der Wal, Eelo Gitz, Vivian X. Du, Kimberly S.L. Lo, Cornelis A. Koekman, abine Versteeg, and Jan Willem N. Akkerman*



Official Organ of the  
European Hematology Association

Stem Cell Transplantation

- 1523** Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study  
*Birgit Federmann, Martin Bornhauser, Christoph Meisner, Lambros Kordelas, Dietrich W. Beelen, Gernot Stuhler, Matthias Stelljes, Rainer Schwerdtfeger, Maximilian Christopeit, Gerhard Behre, Christoph Faul, Wichard Vogel, Michael Schumm, Rupert Handgretinger, Lothar Kanz, and Wolfgang A. Bethge*

Graft-Versus-Host Disease

- 1532** A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease  
*Maria Cuzzola, Maurizio Fiasché, Pasquale Iacopino, Giuseppe Messina, Massimo Martino, Giuseppe Console, Roberta Fedele, Daniela Massi, Anna Grazia Recchia, Giuseppe Irrera, and Fortunato Morabito*

Cell Therapy and Immunotherapy

- 1539** RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia  
*Sylvia Snauwaert, Stijn Vanhee, Glenn Goetgeluk, Greet Verstichel, Yasmine Van Caeneghem, Imke Velghe, Jan Philippé, Zwi N. Berneman, Jean Plum, Tom Taghon, Georges Leclercq, Kris Thielemans, Tessa Kerre, and Bart Vandekerckhove*

Infectious Complications in Hematology

- 1548** Variations in non-pharmacological anti-infective measures in childhood leukemia – results of an international survey  
*Thomas Lehrnbecher, Richard Aplenc, Fernanda Rivas Pereira, Alvaro Lassaletta, Désirée Caselli, Jerzy Kowalczyk, Julia Chisholm, and Lillian Sung on behalf of the SIOP Supportive Care Working Group*

Chronic Myeloid Leukemia

- 1553** Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials  
*Min Tang, Jasmine Foo, Mithat Gönen, Joëlle Guilhot, François-Xavier Mahon, and Franziska Michor*

- 1562** High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients – final analysis of a randomized, multicenter, phase III trial  
*Andreas L. Petzer, Dominic Fong, Thomas Lion, Irina Dyagil, Zvenyslava Masliak, Andrija Bogdanovic, Laimonas Griskevicius, Sandra Lejniece, Stefan Goranov, Liana Gercheva, Aleksandar Stojanovic, Dontcho Peytchev, Nikolay Tzvetkov, Rasa Griniute, Atanas Stanchev, Thomas Grubinger, Marthin Kwakkelstein, Peter Schuld, Guenther Gastl, and Dominik Wolf*

Chronic Myeloproliferative Disorders

- 1570** Experience with pegylated interferon  $\alpha$ -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients  
*Kristina Gowin, Prakash Thapaliya, Jan Samuelson, Claire Harrison, Deepti Radia, Bjorn Andreasson, John Mascarenhas, Alessandro Rambaldi, Tiziano Barbui, Catherine J. Rea, John Camoriano, Amy Gentry, Jean-Jacques Kiladjian, Casey O'Connell, and Ruben Mesa*

- 1574** Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis  
*Markus Ditschkowski, Ahmet H. Elmaagacli, Rudolf Trenscher, Tanja Gromke, Nina K. Steckel, Michael Koldehoff, and Dietrich W. Beelen*

- 1582** Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow  
*Susanne Schnittger, Ulrike Bacher, Christiane Eder, Frank Dicker, Tamara Alpermann, Vera Grossmann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, and Torsten Haferlach*

Pediatric Acute Lymphoblastic Leukemia

- 1586** Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia  
*Giuseppe Gaipa, Giovanni Cazzaniga, Maria Grazia Valsecchi, Renate Panzer-Grümayer, Barbara Buldini, Daniela Silvestri, Leonid Karawajew, Oscar Maglia, Richard Ratei, Alessandra Benetello, Simona Sala, Angela Schumich, Andre Schrauder, Tiziana Villa, Marinella Veltroni, Wolf-Dieter Ludwig, Valentino Conter, Martin Schrappe, Andrea Biondi, Michael N. Dworzak, and Giuseppe Basso*



Official Organ of the  
European Hematology Association

Non-Hodgkin's Lymphoma

- 1594** Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA  
*Marie-Hélène Delfau-Larue, Laurence de Leval, Bertrand Joly, Anne Plouquet, Dominique Challine, Marie Parrens, Alain Delmer, Gilles Salles, Franck Morschhauser, Richard Delarue, Pauline Brice, Reda Bouabdallah, Olivier Casanovas, Hervé Tilly, Philippe Gaulard, and Corinne Haioun*

Multiple Myeloma

- 1603** Thrombosis is associated with inferior survival in multiple myeloma  
*Sigurdur Y. Kristinsson, Ruth M. Pfeiffer, Magnus Björkholm, Sam Schulman, and Ola Landgren*
- 1608** Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?  
*Sergio Matarraz Bruno Paiva, María Díez-Campelo, Lucía-López Corral, Estefanía Pérez, María-Victoria Mateos, Pilar Giraldo, Miguel T. Hernández, Jesús F. San Miguel, and Alberto Orfao on behalf of the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Co-operative Study Groups*

Letters

- 1612** *ETS1* encoding a transcription factor involved in B-cell differentiation is recurrently deleted and down-regulated in classical Hodgkin's lymphoma  
*Birte Malaika Overbeck, Jose Inaki Martin-Subero, Ole Ammerpohl, Wolfram Klapper, Reiner Siebert, and Maciej Giefing*

- 1614** Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma  
*Monika Schmelz, Santiago Montes-Moreno, Miguel Piris, Sarah T. Wilkinson, and Lisa M. Rimsza*

Online-Only Articles

- e37** Aurora-B expression may not contribute to disease progression: a reflection of the heterogeneous pathogenesis?  
*Fabiola Fernandes Heredia, Juliana Cordeiro de Sousa, Alex Fiorini Carvalho, Silvia Maria Meira Magalhaes, and Ronald Feitosa Pinheiro*
- e40** Reply to "Aurora-B expression may not contribute to disease progression: a reflection of the heterogeneous pathogenesis?"  
*Haematologica 2012;97(10):e37-39. Akira Yoshida*
- e41** The diagnostic role of galactomannan during antifungal prophylaxis. Comment on: "The role of antifungal treatment in hematology".  
*Haematologica 2012;97(3):325-7 Corrado Girmenia and Salvatore Perrone*

Continuing Medical Education

Infections in myelodysplastic syndromes

Determinants of outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis

Pegylated interferon alpha-2a in advanced myeloproliferative neoplasms

Rituximab in angioimmunoblastic T-cell lymphoma